Pediatric Cancer Studies: US FDA Eyes Waiver Framework For Same-In-Class Drugs
Executive Summary
Advisory committee says planned waivers for molecularly targeted studies should take into account comparative adult efficacy and toxicity data for multiple drugs in the same class, as well as differences in product attributes, such as route of administration and dosing schedule; unmet clinical need should have less influence on decision to grant waivers, panelists said.